AstraZeneca (LON:AZN) Given “Overweight” Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of AstraZeneca (LON:AZNFree Report) in a research note published on Tuesday, MarketBeat Ratings reports.

A number of other equities analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a hold rating and set a £105 ($134.53) price target on shares of AstraZeneca in a report on Tuesday, April 23rd. Shore Capital restated a buy rating on shares of AstraZeneca in a report on Tuesday, May 21st. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Berenberg Bank lifted their price target on shares of AstraZeneca from £120 ($153.75) to £130 ($166.56) and gave the company a buy rating in a research report on Friday, May 3rd. Finally, Citigroup reiterated a buy rating on shares of AstraZeneca in a research report on Tuesday, May 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. According to data from, the stock currently has an average rating of Moderate Buy and a consensus price target of £118 ($151.19).

View Our Latest Report on AZN

AstraZeneca Stock Performance

AZN opened at £124.64 ($159.69) on Tuesday. The business’s 50-day moving average price is £116.25 and its two-hundred day moving average price is £107.85. AstraZeneca has a 1 year low of GBX 9,461 ($121.22) and a 1 year high of £125.68 ($161.02). The company has a market capitalization of £193.19 billion, a price-to-earnings ratio of 3,975.64, a P/E/G ratio of 0.97 and a beta of 0.16. The company has a debt-to-equity ratio of 92.51, a current ratio of 0.89 and a quick ratio of 0.59.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.